美国批准了一个用于体重管理的口服Wegovy药丸,于2026年1月5日推出,价格从每月149美元到299美元不等。 The U.S. has approved an oral Wegovy pill for weight management, launching January 5, 2026, with pricing from $149 to $299 monthly.

经林业发展局于2025年12月核准后,美国现在向肥胖或超重成年人提供含有硫酸盐的口服Wegovy药丸。 The oral Wegovy pill, containing semaglutide, is now available in the U.S. for adults with obesity or overweight, following FDA approval in December 2025. 在2026年1月5号发射时,它提供每日平板药选项,每月149美元至299美元,视剂量而定,根据Trump管理协议,首服价格较低。 Launching January 5, 2026, it offers a daily tablet option at $149 to $299 per month, depending on dosage, with lower prices for starter doses under a Trump administration deal. 药丸必须空着肚子服用,30分钟后不得进食或饮酒。 The pill must be taken on an empty stomach with no food or drink for 30 minutes afterward. 在70 000多个药店和通过远程保健提供者提供。 It is available at over 70,000 pharmacies and through telehealth providers. 临床试验显示,体重减重和副作用相似,如恶心和呕吐,与可注射的版本相似。 Clinical trials show similar weight loss and side effects—like nausea and vomiting—as the injectable version. 竞争者Eli Lilly的口服GLP-1药物预计将在2026年晚些时候得到林业发展局的批准。 Competitor Eli Lilly’s oral GLP-1 drug is expected for FDA approval later in 2026.